{"url":"https://lda.senate.gov/api/v1/filings/456c00ba-e899-45ed-b1bf-d49ea715a842/","filing_uuid":"456c00ba-e899-45ed-b1bf-d49ea715a842","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/456c00ba-e899-45ed-b1bf-d49ea715a842/print/","filing_document_content_type":"text/html","income":null,"expenses":"670000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Christine Bloomquist","dt_posted":"2025-01-20T11:25:46-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2375 Waterview Drive","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Northbrook","registrant_state":"IL","registrant_zip":"60062","registrant":{"id":40032268,"url":"https://lda.senate.gov/api/v1/registrants/40032268/","house_registrant_id":39903,"name":"ASTELLAS PHARMA US, INC.","description":"Pharmaceuticals","address_1":"2375 Waterview Drive","address_2":null,"address_3":null,"address_4":null,"city":"Northbrook","state":"IL","state_display":"Illinois","zip":"60062","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JOHN OEHMEN","contact_telephone":"+1 202-304-0168","dt_updated":"2026-07-30T14:48:38.939088-04:00"},"client":{"id":188248,"url":"https://lda.senate.gov/api/v1/clients/188248/","client_id":12,"name":"ASTELLAS PHARMA US, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-17"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.","foreign_entity_issues":"Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.","lobbyists":[{"lobbyist":{"id":107392,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"OEHMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":113234,"prefix":null,"prefix_display":null,"first_name":"AKSHAI","nickname":null,"middle_name":null,"last_name":"DATTA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.","foreign_entity_issues":"Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.","lobbyists":[{"lobbyist":{"id":107392,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"OEHMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":113234,"prefix":null,"prefix_display":null,"first_name":"AKSHAI","nickname":null,"middle_name":null,"last_name":"DATTA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Issues related to Bayh-Dole Act (Pub.L. 96-517).","foreign_entity_issues":"Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.","lobbyists":[{"lobbyist":{"id":107392,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"OEHMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":113234,"prefix":null,"prefix_display":null,"first_name":"AKSHAI","nickname":null,"middle_name":null,"last_name":"DATTA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).","foreign_entity_issues":"Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.","lobbyists":[{"lobbyist":{"id":107392,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"OEHMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":113234,"prefix":null,"prefix_display":null,"first_name":"AKSHAI","nickname":null,"middle_name":null,"last_name":"DATTA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}